Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 78Osteosarcoma 34Melanoma 22Sarcoma, Ewing 20Neuroblastoma 19Rhabdomyosarcoma 17Ovarian Neoplasms 17Gastrointestinal Stromal Tumors 17Colorectal Neoplasms 16Glioblastoma 15Bone Neoplasms 15Sarcoma, Kaposi 14Rhabdoid Tumor 14Neoplasms 14Breast Neoplasms 14Wilms Tumor 13Liposarcoma 13Neoplasm Metastasis 12Gliosarcoma 12Medulloblastoma 11Lymphoma, Non-Hodgkin 11Hepatoblastoma 11Glioma 11Carcinoma, Non-Small-Cell Lung 11Stomach Neoplasms 10Neurofibrosarcoma 10Thyroid Neoplasms 9Recurrence 9Pancreatic Neoplasms 9Ependymoma 9

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Sarcoma × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡